Selective Serotonin Reuptake Inhibitors (SSRIs) in Borderline Personality Disorder

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Borderline Personality Disorder

In brief

The goal of this study is to examine the effectiveness the selective serotonin reuptake inhibitor (SSRI) escitalopram (also known by the trade name "Lexapro") in reducing desire to self-harm and actual self-harming among young adults with borderline personality disorder who are also currently depressed. Subjects will receive either escitalopram or placebo for eight weeks. During this time subjects will be make weekly visits to see the psychiatrist and record their thoughts and feelings several times each day using an electronic diary.

Key facts

Study ID

NCT01103180

Run by

University of Chicago

People needed

70

Starts

2010-09-01

Expected to finish

2014-11-01

Last updated by the study team

2019-06-14

Who can join

Age: 18 and older, up to 40. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Diagnosis of Borderline Personality Disorder
• Current Major Depression

You may not qualify if…

• Past 2 months SSRI use
• Past 6 months non-SSRI antidepressant use
• Past 2 months initiation of psychotherapy
• Lifetime bipolar disorder, organic disorder, psychotic disorder
• Current alcohol or drug dependence
• Current severe suicidal / homicidal ideation necessitating immediate medical intervention
• Currently pregnancy or nursing
• Unable or unwilling to cooperate with study protocol

Where it is running

• The University of Chicago Hospitals — Chicago, Illinois, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.